J. James

发表

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

P. Zarrinkar, Mazen W. Karaman, G. Pallares, 2009, Blood.

Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor.

Merryl D. Cramer, M. F. Gardner, J. James, 2005, Bioorganic & medicinal chemistry letters.

3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2).

A. Pinkerton, M. F. Gardner, J. James, 2005, Bioorganic & medicinal chemistry letters.

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

P. Zarrinkar, J. Cortes, F. Giles, 2007 .

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

H. Kantarjian, J. Cortes, G. Borthakur, 2009 .

A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

E. Estey, H. Döhner, H. Dombret, 2011 .

Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.

L. Bristow, J. James, T. Kamenecka, 2005, Bioorganic & medicinal chemistry letters.

Influence of acid surrogates toward potency of VLA-4 antagonist.

S. Venkatraman, B. Muñoz, Merryl D. Cramer, 2005, Bioorganic & medicinal chemistry letters.

Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators.

A. Pinkerton, J. James, U. Campbell, 2005, Bioorganic & medicinal chemistry letters.

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.

D. K. Treiber, Zdravko V. Milanov, R. Armstrong, 2011, Bioorganic & medicinal chemistry letters.

CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012, Molecular Cancer Therapeutics.

Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

D. K. Treiber, Brian T. Campbell, R. Armstrong, 2012, ACS medicinal chemistry letters.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

H. Kantarjian, J. Cortes, G. Borthakur, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Development CEP-32496 : A Novel Orally Active BRAFV 600 E Inhibitor with Selective Cellular and In Vivo Antitumor Activity

Raffaella Faraoni, Darren E. Insko, P. Dobrzanski, 2012 .

An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia

J. James, G. Gammon, Jianke Li, 2017, Xenobiotica; the fate of foreign compounds in biological systems.

Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR.

W. Denny, G. Rewcastle, D. J. Matthews, 2011 .

Clinical Pharmacokinetics and FLT3 Phosphorylation of AC220, a Highly Potent and Selective Inhibitor of FLT3

P. Zarrinkar, Darren E. Insko, M. Levis, 2008 .

treatment of acute myeloid leukemia (AML) AC220 is a uniquely potent and selective inhibitor of FLT3 for the

P. Zarrinkar, Mazen W. Karaman, G. Pallares, 2013 .

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.

Brian T. Campbell, Raffaella Faraoni, Andiliy G. Lai, 2011, Bioorganic & Medicinal Chemistry Letters.

Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators.

A. Pinkerton, J. James, J. Vernier, 2004, Bioorganic & medicinal chemistry letters.

METABOLISM AND DISPOSITION OF A POTENT GROUP II METABOTROPIC GLUTAMATE RECEPTOR AGONIST, IN RATS, DOGS, AND MONKEYS

A. Nakazato, Merryl D. Cramer, J. James, 2005, Drug Metabolism and Disposition.

Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers

J. James, T. Hashimoto, S. Gill, 2012 .

A. Ghose, Brian T. Campbell, Raffaella Faraoni, 2012, Journal of medicinal chemistry.

P. Zarrinkar, H. Patel, T. Carter, 2009, Journal of medicinal chemistry.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

P. Zarrinkar, Mazen W. Karaman, H. Patel, 2009, Blood.

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

D. Lockhart, P. Zarrinkar, D. K. Treiber, 2009, Bioorganic & medicinal chemistry letters.